EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report

Chunqian Shi, Tong Cai, Mei Yue, Huijuan Ma, Qingfen Qin, Qian Song

TH Open · 2026-08-11 · 10 (CP)

DOI: 10.1055/a-2923-1469 ↗
AbstractBibliografische Angaben

Abstract

Abstract Heparin-induced thrombocytopenia (HIT) with thrombosis typically necessitates immediate therapeutic-dose anticoagulation, yet management becomes exceedingly complex when a profound bleeding risk coexists. We report a unique case of serologically confirmed HIT developing during low-molecular-weight heparin prophylaxis following major trauma in a 67-year-old man. On day 10 of heparin exposure, the patient presented with a platelet count declining from 169 × 109/L to 20 × 109/L (91% reduction), hypofibrinogenemia (1.12 g/L), extensive deep vein thrombosis, and pulmonary embolism. Owing to extreme bleeding risk, argatroban initiation was deferred for 48 hours postdiagnosis, then cautiously titrated from 0.08 to 0.67 μg/kg/min guided by dynamic coagulation–fibrinolysis markers (thrombin–antithrombin complex, plasmin–α2-antiplasmin complex, and D-dimer). These markers provided real-time assessment of treatment response, declining substantially prior to platelet count normalization. By day 12 postdiagnosis, platelet count recovered to 176 × 109/L, permitting successful definitive orthopedic surgery on day 13 without bleeding complications. This case illustrates that in HIT with life-threatening thrombosis and extreme bleeding risk, an individualized “start low, go slow” argatroban strategy with delayed initiation achieves effective anticoagulation while minimizing hemorrhagic risk.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →